Rapid response to a college outbreak of meningococcal serogroup B disease: Nation's first widespread use of bivalent rLP2086 vaccine.
J Am Coll Health
; 65(4): 294-296, 2017.
Article
in En
| MEDLINE
| ID: mdl-28121236
ABSTRACT
OBJECTIVE:
To outline the reasoning behind use of bivalent rLP2086 in a Rhode Island college meningococcal B disease outbreak, highlighting the timeline from outbreak declaration to vaccination clinic, emphasizing that these two time points are <3 days apart.PARTICIPANTS:
Staff, faculty, and students at College X eligible for vaccination.METHODS:
An outbreak response was initiated, advantages/disadvantages of available MenB vaccines were discussed, and a vaccination clinic was coordinated.RESULTS:
Bivalent rLP2086 was chosen as the vaccination intervention. We achieved a 94% coverage rate for the first dose. To date, this intervention has prevented further cases of Neisseria meningitidis serogroup B disease at College X.CONCLUSIONS:
The close, efficient collaboration of public health stakeholders and College X led 94% of the eligible population to be safely vaccinated with at least one dose of bivalent rLP2086. This outbreak marked the first time bivalent rLP2086 was effectively used as an intervention response.Key words
Full text:
1
Collection:
01-internacional
Health context:
1_ASSA2030
/
3_ND
/
4_TD
Database:
MEDLINE
Main subject:
Universities
/
Disease Outbreaks
/
Civil Defense
/
Meningococcal Vaccines
Limits:
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
J Am Coll Health
Year:
2017
Document type:
Article